We evaluated the relationship between NE expression and well-known prognostic factors and assessed whether tumor relapse after radical surgery correlates with the extent of NE differentiation. Radical prostatectomy specimens from 110 patients with clinically localized prostate cancer were assessed. Patients were followed up every three months for the first two years after surgery and six monthly for 5 additional years until failure, or for a mean of 48 months from the time of surgery for those who did not experience failure. The percentage of cells showing CgA immunoreactivity was evaluated using a visual quantitative method. Tumor staining was categorized as positive if>10% and negative if <10% of tumor cells were stained, to ensure that only cases with significant positivity were included in the positive group. The median follow-up was 5.4 years (range 1.8 to 7.2). The median time to clinical recurrence was 7.5 years and the median time to biochemical recurrence was 2.8 years. Of 31 patients (28%) who experienced a PSA recurrence, 15 developed a clinical recurrence. The mean preoperative PSA level was 9 ng/ml (range 2.7 to 25). Most cases were well differentiated (Gleason score <7), intraprostatic (:spT2) tumors. Immunoreactivity in ;:::10% of the cells was seen in 17.2% (n=19) of the tumor specimens. The preoperative PSA level, Gleason score, use of neoadjuvant or adjuvant therapy, Iymphnode positivity were not statistically associated with NE expression. Only the primary pathologic stage appeared to be associated with CgA staining in the primary tumor (p=O.OOI). On the univariate analysis NE expression did not predict biochemical recurrence free survival, whereas it was associated with clinical recurrence. NE differentiation in clinically localized prostate cancer can be associated with failure after definitive surgical treatment, even if no conclusions can be drawn regarding its value as an independent prognostic factor.
Chromogranin A (CgA) is consistently expressed during NE cell differentiation (6) . Studies published to date have suggested that CgA determined by immuno-histochemistry or serum assay is a significant predictor of the outcome of hormonal therapy (7) . However, its role as a marker ofrecurrence after radical prostatectomy (RP) is still unclear (8) .
The aim ofthis study is to evaluate the relationship between NE expression and well-known prognostic factors and to assess whether tumor relapse after radical surgery correlates with the extent of NE differentiation.
MATERIALS AND METHODS
Radical prostatectomy specimens from 110 patients with clinically localized prostate cancer were assessed. Of these, 50 (45%) had received neoadjuvant hormonal therapy. Adjuvant treatment, including a LHRH agonist alone or in combination with an anti-androgen and/or postoperative radiotherapy started within 3 months of surgery, was given to 44 (40%).
All patients were followed up every three months for the first two years after surgery and six monthly for an 5 additional years, until failure, or for a mean of 48 months from the time of surgery for those who did not experience failure. A serum PSA value greater than 0.4 ng/ml on two consecutive measurements was considered to indicate biochemical recurrence (9) .
Pathology
Formalin-fixed paraffin-embedded tissue blocks corresponding to the tumor were selected, form which 4 /lI11 sections were cut into polylysine slides. Slides containing the tumor were chosen if they included a representative section of the primary Gleason pattern and areas ofevaluable benign epithelium. Deparaffinization was performed with xylene and the tissue was rehydrated in graded ethanol solutions and rinsed in tap water. The slides were buffered with dilute hydrogen peroxide and blocked with 20% fetal bovine serum and then incubated overnight at 4°C with I: 1000 dilution of a monoclonal antibody against CgA (OAK-A, Dako, Italy). After incubation, immunodetection was performed following a standard avidin-biotin complex method (LSAB-DAKO, Italy and DAB, USA). All the slides were reviewed by two pathologists who had no knowledge of the clinical data.
The percentage ofcells showing CgA immunoreactivity was evaluated using a visual quantitative method. Tumor staining was categorized as positive if> 10% and negative if <10% of tumor cells were stained, to ensure that only cases with significant positivity were included in the positive group. On this basis, cases with very occasional positive cells were designated negative, as most tumours had occasional positive cells.
Statistics
Kaplan-Meier curves were calculated to determine the biochemical recurrence free survival. The log-rank test was used to compare survival outcome among different subgroups. Estimates of the hazard ratio were based on log-rank statistics. The Pearson chi-square test or Fisher's exact test was used to evaluate the association between different clinical variables and the results of NE staining, classified as negative versus positive. All statistical tests were two-sided, and p < 0.05 was considered statistically significant.
RESULTS
The median follow-up was 5.4 years (range 1.8 to 7.2), with all having at least 2 years offollow-up. The median time to clinical recurrence was 7.5 years and the median time to biochemical recurrence was 2.8 years. Of 31 patients (28%) who experienced a PSA recurrence, 15 developed a clinical recurrence.
The mean age was 65 (range 52-77). The clinical and histopathologic characteristics are summarized in Table I . The mean preoperative PSA level was 9 ng/ml (range 2.7 to 25). Most cases were well differentiated (Gleason score <7), intraprostatic (~pT2) tumors. Immunoreactivity in 2:10% of the cells was seen in 17.2% (n=19) of the tumor specimens. Fig. 1 shows a positive and negative immunohistochemical expression. The preoperative PSA level, Gleason score, use of neoadjuvant or adjuvant therapy, and lymphnode positivity were not statistically associated with NE expression. Only the primary pathologic stage appeared to be associated with CgA staining (p=O.OO 1).
On the univariate analysis (Table II) , NE expression did not predict biochemical recurrence free survival, whereas it was associated with clinical recurrence.
Given the relatively small number of patients with NE expression, a multivariate analysis using the Cox proportional hazard model was not advisable. Instead, to obtain preliminary information regarding whether NE expression was an independent predictor of outcome, a stratified log-rank test statistic was calculated, adjusting for each clinical variable (Table  III) . After stratification, p values <0.05 in unstratified analysis remained significant or nearly, except after 
DISCUSSION
The reported incidence of prostatic adenocarcinomas with dispersed NE differentiation varies from 10 to 92%. Sample size and technical aspects, such as tissue fixation and staining methods, may explain this variation between different studies (10) . In our experience NE differentiation represented only the 17.2% of all the patients.
The cut off for CgA positivity in our study was 10%, regarding the tumor cell count, as suggested by others and more recently also by Kokubo H et al (11), therefore, our pathologists used a quantitative .. evaluation system to detect the NE staining in the slides. To note that there is no standard scoring methodology to evaluate CgA expression, since it represents a field of ongoing research in the biology of prostate cancer. Moreover, our sample size was too small to make a more complex immunohistochemical evaluation and we chose a simplified method which could differentiate between those samples with a representative NE pattern and those without a significant NE pattern. The clinical and prognostic significance of these changes, however, remains poorly understood. Cohen et al reported that NE differentiation in tumor specimens could predict survival more accurately than Gleason score (12) . Other studies did not demonstrate a prognostic value ofNE differentiation in prostate cancer (13) (14) . Krijnen et al showed that NE differentiation is associated with early hormone therapy failure, indicating that these cells are androgen independent (15) . Bonkhoff et al found that the rate of proliferation of prostate cancer in the vicinity of NE differentiation is higher (16) .
Alghren et al found a significant increase in the number of CgA-positive cells after 3 months hormonal treatment as compared with non-treated control group (17) . Whether these findings are of biological significance remains questionable. In another subsequent study they evaluate whether this increase in NE cells had any impact on failure after RP and found that NE differentiation is not per se a prognostic factor (8) . Van de Voorde et al studied morphologic and immunohistochemical changes in prostate cancer treated by RP after NHT. NE differentiation as indicated by CgA expression was seen in 95% of tumors only in restricted areas, while a diffusely dispersed staining was seen in fewer tumors. The authors noted an increased expression of CgA with more advanced stage and with increasing tumor volume (18) . Weinstein et al studied 104 patients with clinically localized prostate cancer treated by RP and they found histological grade and NE differentiation predicted progression in a multivariate analysis. They found NE differentiation particularly useful in predicting prognosis for intermediate Gleason score (9) (10) tumors (19) . On the contrary, Cohen et al studied 38 patients with stage 11 prostate cancer for 4 years after RP and did not find NE differentiation useful in predicting tumor progression (20) . Theodorescu et al showed that NE differentiation predicted patient survival in 71 patients with stage Tl-2 prostate cancer, but only on univariate analysis (21) .
Pruneri et al reported that CgA-positive cells more frequently occurred in patients with a Gleason score >6 compared with patients with a score <6 (22) .
Although no strong statistical association was found with known clinical and histopathologic parameters, such as PSA level, Gleason score and node status, NE expression appeared to be associated with the primary tumor stage (NE cells were greatest in patients with pT3 tumors). NE expression was associated with earlier clinical recurrence on univariate analysis, as shown in Table II .
To ascertain whether these were independent associations, analyses were rerun, stratifying by each clinical and histopathologic variable. On the basis of these analyses, the associations observed univariately remained unchanged except when stratifying by tumor stage. Therefore, NE expression may be a reflection of primary tumor stage or NE expression may be strongly associated with outcome in a subset of patients.
Several potential limitations of this study should be mentioned. Firstly, this was a retrospective cohort study with the inherent selection biases. Secondly, differences in the immunohistochemical method and its interpretation might explain some of the variability in NE expression and predictive value reported in published series. Moreover, we used only one NE marker. Despite these limitations, the present study provides further insight into the role of NE expression in human prostate cancer as a possible prognostic biomarker.
In conclusion, NE differentiation in clinically localized prostate cancer can be associated with failure after definitive surgical treatment, even if no conclusions can be drawn regarding its value as an independent prognostic factor. The clinical significance ofNE differentiation in the progression of the disease after radical prostatectomy remains to be further addressed.
